Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases

[1]  K. Schimrigk,et al.  Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type , 1997, Biological Psychiatry.

[2]  J. Marksteiner,et al.  Rat Brain: Distribution of Immunoreactivity of PE‐11, a Peptide Derived from Chromogranin B , 1996, The European journal of neuroscience.

[3]  M. Marcinkiewicz,et al.  Kainic acid increases the expression of the prohormone convertases furin and PC1 in the mouse hippocampus , 1996, Brain Research.

[4]  A. Laslop,et al.  Processing of chromogranins in chromaffin cell culture: effects of reserpine and alpha-methyl-p-tyrosine. , 1996, The Biochemical journal.

[5]  A. Benzer,et al.  CSF of neuroleptic-naive first-episode schizophrenic patients: Levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin) , 1996, Biological Psychiatry.

[6]  R. Fischer‐Colbrie,et al.  Secretogranin II: Relative Amounts and Processing to Secretoneurin in Various Rat Tissues , 1996, Journal of neurochemistry.

[7]  R. Possenti,et al.  Tissue‐Specific Processing of the Neuroendocrine Protein VGF , 1995, Journal of neurochemistry.

[8]  K. Blennow,et al.  Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? , 1995, Dementia.

[9]  L. Eiden,et al.  Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway , 1995, Regulatory Peptides.

[10]  J. Marksteiner,et al.  Large variations in the proteolytic formation of a chromogranin A-derived peptide (GE-25) in neuroendocrine tissues. , 1995, The Biochemical journal.

[11]  A. Laslop,et al.  Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin , 1995, Progress in Neurobiology.

[12]  D. Aunis,et al.  Processing of chromogranin B in bovine adrenal medulla. Identification of secretolytin, the endogenous C-terminal fragment of residues 614-626 with antibacterial activity. , 1995, European journal of biochemistry.

[13]  J. Marksteiner,et al.  Molecular characterization of immunoreactivities of peptides derived from chromogranin a (GE-25) and from secretogranin II (secretoneurin) in human and bovine cerebrospinal fluid , 1994, Neuroscience.

[14]  R. Takayanagi,et al.  Pancreastatin-like immunoreactivity of cerebrospinal fluid in patients with Alzheimer type dementia: evidence of aberrant processing of pancreastatin in Alzheimer type dementia , 1994, Neuroscience Letters.

[15]  H. Gerdes,et al.  The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors , 1994, Journal of endocrinological investigation.

[16]  R. Kirchmair,et al.  Attraction of human monocytes by the neuropeptide secretoneurin , 1993, FEBS letters.

[17]  D. O'Connor,et al.  Chromogranin a immunoreactivity in human cerebrospinal fluid: Properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease , 1993, Neuroscience.

[18]  R. Kirchmair,et al.  Secretoneurin releases dopamine from rat striatal slices: A biological effect of a peptide derived from secretogranin II (chromogranin C) , 1993, Neuroscience.

[19]  R. Kirchmair,et al.  Secretoneurin—a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C) , 1993, Neuroscience.

[20]  R. Fischer‐Colbrie,et al.  The chromogranins A and B: The first 25 years and future perspectives , 1992, Neuroscience.

[21]  N. Seidah,et al.  Distribution and regulation of the prohormone convertases PC1 and PC2 in the rat pituitary. , 1992, Molecular endocrinology.

[22]  R. Mains,et al.  Prohormone-converting enzymes: regulation and evaluation of function using antisense RNA. , 1991, Molecular endocrinology.

[23]  T. Hökfelt.  Neuropeptides in perspective: The last ten years , 1991, Neuron.

[24]  M. Ghatei,et al.  Regional distribution of chromogranin B 420–493-like immunoreactivity in the pituitary gland and central nervous system of man, guinea-pig and rat , 1989, Neuroscience.

[25]  C H Lücking,et al.  Essential tremor: electrophysiological and pharmacological evidence for a subdivision. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[26]  J. Mallet,et al.  The primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. , 1987, The EMBO journal.

[27]  N. Seidah,et al.  Immunocytochemical localization of a novel pituitary protein (7B2) within the rat brain and hypophysis. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  P. De Camilli,et al.  Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway , 1985, The Journal of cell biology.

[29]  R. Fischer‐Colbrie,et al.  Immunological Characterization of Secretory Proteins of Chromaffin Granules: Chromogranins A, Chromogranins B, and Enkephalin‐Containing Peptides , 1985, Journal of neurochemistry.

[30]  P. Rosa,et al.  Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis II. Sulfated and glycosylated polypeptides , 1981, Molecular and Cellular Endocrinology.

[31]  A. D. Smith,et al.  Secretion from the adrenal medulla: biochemical evidence for exocytosis. , 1967, British journal of pharmacology and chemotherapy.

[32]  A. D. Smith,et al.  Secretion of a Chromaffin Granule Protein, Chromogranin, from the Adrenal Gland after Splanchnic Stimulation , 1967, Nature.

[33]  J. Málly,et al.  Potential role of adenosine antagonist therapy in pathological tremor disorders. , 1996, Pharmacology & therapeutics.

[34]  J. Lieberman,et al.  Neurochemistry and neuroendocrinology of schizophrenia: a selective review. , 1993, Schizophrenia bulletin.